CD274 and neoplasm: Immune checkpoint inhibitors (ICIs), including antibodies targeting programmed death 1 (PD-1) and its ligand (PD-L1), have demonstrated the ability to restore anti-tumor immunity by enhancing T cell-mediated tumor recognition (15).